Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
45results about How to "Blocking interaction" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Preparation method of anti-tobacco potato Y virus vaccine
InactiveCN105420264AReduce duplicationStrong specificityBiocideDisinfectantsNicotiana tabacumPotato virus Y PVY
The invention discloses a preparation method of an anti-tobacco potato Y virus vaccine. The method includes the following steps that 1, pCaPVX440-eIF4E-6 plasmids are prepared; 2, the pCaPVX440-eIF4E-6 is transferred to agrobacterium to prepare the anti-tobacco potato Y virus vaccine. The anti-tobacco potato Y virus vaccine prepared by means of the preparation method is suitable for prevention and control of tobacco PVY viruses and has an important practical value for prevention and control of diseases caused by the PVY viruses in the tobacco leaf production process. Compared with the prior art, the virus vaccine is good in specificity, good in safety, simple, convenient and quick to operate and low in cost.
Owner:中国烟草总公司黑龙江省公司烟草科学研究所 +1
Detection kit for human leucocyte antigen genes
PendingCN104862379ABlocking interactionMicrobiological testing/measurementBiological testingMetaboliteHLA - Human leukocyte antigen gene
The invention belongs to the technical field of biological medicines and relates to a detection kit for human leucocyte antigen (HLA) genes--HLA-B*59: 01 genes, and the HLA-B*59: 01 genes can serve as marker genes for forecasting methazolamide caused SJS (Stevens-Johnson syndrome) and TEN (Toxic epidermal necrolysis). According to the detection kit, after DNA extracted from the peripheral blood of a patient, the PCR-SSO method is adopted to detect the HLA-B*59 :01 genes. The detection kit for HLA-B*59: 01 genes can be used for examining before application of methazolamide and screening targeted medicines for treating methazolamide caused SJS and TEN; and examination can guide clinical medication to reduce incidence of SJS and TEN caused by methazolamide, and the screening mainly acts on HLA-B*59: 01 molecules in a targeted manner, so that interaction between the HLA-B*59: 01 molecules and methazolamide or other metabolic products during attack.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV +1
Human leukocyte antigen gene detection kit for screening skin drug adverse reactions caused by salazosulfapyridine
ActiveCN104818316ABlocking interactionMicrobiological testing/measurementBiological testingMetaboliteWhite blood cell
The invention provides a human leukocyte antigen gene detection kit for screening skin drug adverse reaction caused by salazosulfapyridine, belongs to the technical field of biomedicine, and relates to a detection kit of human leukocyte antigen gene HLA-B*13:01, wherein the HLA-B*13:01 gene can be adopted as the marker gene of salazosulfapyridine-induced DRESS. According to the present invention, DNA is extracted from the peripheral blood of a patient, and the HLA-B*13:01 gene is detected by using the current method, such as PCR-SSO (sequence-specific oligonucleotide probe) method; and the HLA-B*13:01 gene detection kit of the present invention can be used for screening before the salazosulfapyridine use and screening the target drug for treatment of salazosulfapyridine-induced DRESS, wherein the screening before the salazosulfapyridine use can guide the clinical medication so as to reduce the occurrence of the salazosulfapyridine-induced DRESS, and the drug screening mainly act on the HLA-B*13:01 molecules in a targeting manner so as to block the interaction between the HLA-B*13:01 molecules and the salazosulfapyridine or the metabolites thereof in the pathogenesis.
Owner:FUDAN UNIV +1
Chimeric antigen recipient cell taking ROBO1 as target, preparation and application thereof
PendingCN108977453AImprove anti-tumor effectBlocking interactionPeptide/protein ingredientsAntibody mimetics/scaffoldsAbnormal tissue growthAntigen
The invention discloses a chimeric antigen recipient cell taking ROBO1 as a target, a preparation and an application thereof and especially discloses a reinforced CAR-T cell and CAR-NK cell taking ROBO1 as the target. The cell is capable of stably expressing CAR element while performing secretory expression on extracellular domain molecules or mutants of PD-1 protein and stopping the interaction of PD-1 / PD-L1 molecules. An animal test proves that the cell has an excellent anti-tumor effect, and the cell, compared with a common CAR modified cell taking ROBO1 as the target, is capable of obviously reducing recurrence rate of tumors and increasing survival rate.
Owner:ASCLEPIUS SUZHOU TECH CO GRP CO LTD
CD47/SIRP (signal regulatory protein) alpha blocking agent and application thereof
The invention relates to a compound of a blocking agent for CD47 / SIRP alpha interaction, in particular to a compound as shown in a formula I, a medicine composition containing the compound as shown inthe formula I and an application of the compound to treatment of CD47 / SIRP alpha interaction mediated diseases and preparation of a medicine for treating the CD47 / SIRP alpha interaction mediated diseases.
Owner:EAST CHINA UNIV OF SCI & TECH
Application of polypeptide in preparation of medicines for treating or preventing metabolic syndrome
ActiveCN104740605ABlocking interactionRestoring autophagic flowPeptide/protein ingredientsMetabolism disorderAmino acidMetabolic syndrome
The invention discloses an application of a polypeptide specifically bingd to TRB3 or a derivative of the polypeptide in the preparation of medicines for treating and / or preventing metabolic syndrome. The amino acid sequence of the polypeptide is represented by anyone of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3; and the derivative of the polypeptide is a chimeric peptide formed by connecting the polypeptide with a cell penetrating peptide and / or a medicinal composition formed by cooperating the polypeptide with a medicinal assistant. The polypeptide or the polypeptide derivative can specifically bind to the TRB3 in order to block out interaction between the TRB3 and a P62 protein, and the peptide derivatives Pep2-A1, Pep2-A2 and Pep3-A3 can be used to treat high fat diet induced mouse metabolic syndrome.
Owner:胡卓伟
Anti-TIGIT nanobody and application thereof
ActiveCN111718415ABlocking interactionEffective combinationHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsTIGITCD155
The invention discloses an anti-TIGIT nanobody and application thereof, and particularly provides an anti-TIGIT nanobody and a sequence thereof. The invention also provides a coding sequence encodingthe nanobody or a VHH chain thereof, a corresponding expression vector and a host cell capable of expressing the nanobody, as well as a production method of the nanobody. The nanobody can block the interaction between TIGIT and CD155 on the surface of CT26 cells, and can effectively bind to the TIGIT protein on the cell surface; the nanobody can recognize human and macaca fascicularis TIGIT; the blocking activity of the nanobody is significantly better than a control antibody Tiragolumab; and the nanobody has a significant activating effect on T cells, and the activation effect is significantly better than that of the control antibody Tiragolumab.
Owner:SHANGHAI NOVAMAB BIOPHARM CO LTD
Human leukocyte antigen gene detection kit for screening clindamycin-induced adverse drug reactions on skin
ActiveCN106755291ABlocking interactionMicrobiological testing/measurementBiological material analysisAntigenMetabolite
The invention belongs to the technical field of biological medicine, and relates to a human leukocyte antigen HLA-B*51: 01 gene detection kit. An HLA-B*51: 01 gene can be used as a marker gene for predicting clindamycin-induced drug rash. The invention provides the application of the detection kit to typing of the HLA-B*51: 01 gene in a sample. The application comprises the following steps: extracting DNA from obtained peripheral blood of a patient, and detecting the HLA-B*51: 01 gene by a current method, such as a sequence-specific oligonucleotide probe (PCR-SSO) method. The HLA-B*51: 01 gene detection kit provided by the invention can be applied to screening and sifting of targeted drugs for treating the clindamycin-induced drug rash before the use of clindamycin; screening application can guide clinical drug use so as to reduce incidence of the clindamycin-induced drug rash; selecting application mainly acts on an HLA-B*51: 01 molecule in a targeted manner so as to block interaction between the HLA-B*51: 01 molecule and clindamycin or other metabolites during the drug rash.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV +1
Fluorenyl aromatic phosphine oxide photoelectric material and preparation method thereof
InactiveCN102924516ABlocking interactionBalance injectionGroup 5/15 element organic compoundsSolid-state devicesFluorescenceDiphenylphosphine oxide
The invention relates to a photoelectric material and a preparation method thereof, particularly to a fluorenyl aromatic phosphine oxide photoelectric material and a preparation method thereof, and aims at solving the problem that carrier injection transmission is unbalanced caused by the fact that aromatic hydrocarbon or arylamine functional groups with large conjugated structures are introduced into a fluorine system. The method includes preparing 2-bromine-(9,9-bis-(diphenylphosphine oxide) ) fluorine; and mixing the 2-bromine-(9,9-bis-(diphenylphosphine oxide) ) fluorine, tetrakis (triphenylphosphine) palladium, tetrabutylammonium bromide and borate and dissolving in tetrahydrofuran, adding in NaOH solution, and obtaining the photoelectric material after reaction, extraction, drying and column chromatography; or mixing the 2-bromine-(9,9-bis-(diphenylphosphine oxide) ) fluorine, carbazole, potassium carbonate, copper iodide and 18-crown-6-ether, adding in a high-temperature solvent, and obtaining the photoelectric material after reaction, extraction, drying and column chromatography. The power efficiency of the photoelectric material prepared through the method can reach 2.19lm / W when the material is used for preparing blue-ray fluorescent devices.
Owner:HEILONGJIANG UNIV
Bi-functional monoclonal antibody capable of anti-human von willbrand factor-A3
InactiveCN101597595BBinding blockBlocking interactionImmunoglobulins against animals/humansAntibody ingredientsVon Willebrand factorFactor ii
The invention relates to a hybridoma cell strain SZ-125(3D2) with the prevention number of CGMCC NO.2501 and a bi-functional monoclonal antibody capable of anti-human von willbrand factor-A3 secreted by the hybridoma cell strain. The monoclonal antibody is combined with the VWF A3 to block the combination of the VWF A3 and collagen and simultaneously influences the configuration of domain A1, thereby destroying the original domain A1 configuration capable of combining platelet GPIb alpha and achieving the aim of blocking the interaction of the VWF A1 and the GPIb alpha, so that not only combination of the VWF A3 and the collagen is blocked but also the combination of the VWF A1 and the platelet GPIb alpha is blocked. Thus, the monoclonal antibody can be used for preparing anti-artery thrombosis medicine with anti-platelet adhesion activity.
Owner:苏州苏大赛尔免疫生物技术有限公司
Bi-functional monoclonal antibody capable of anti-human von willbrand factor-A3
InactiveCN101597595ABinding blockBlocking interactionImmunoglobulins against animals/humansAntibody ingredientsVon Willebrand factorFactor ii
The invention relates to a hybridoma cell strain SZ-125(3D2) with the prevention number of CGMCC NO.2501 and a bi-functional monoclonal antibody capable of anti-human von willbrand factor-A3 secreted by the hybridoma cell strain. The monoclonal antibody is combined with the VWF A3 to block the combination of the VWF A3 and collagen and simultaneously influences the configuration of domain A1, thereby destroying the original domain A1 configuration capable of combining platelet GPIb alpha and achieving the aim of blocking the interaction of the VWF A1 and the GPIb alpha, so that not only combination of the VWF A3 and the collagen is blocked but also the combination of the VWF A1 and the platelet GPIb alpha is blocked. Thus, the monoclonal antibody can be used for preparing anti-artery thrombosis medicine with anti-platelet adhesion activity.
Owner:苏州苏大赛尔免疫生物技术有限公司
Selenium-rich peptide with high antioxidant activity and application thereof
ActiveCN114478692AIncrease selenium contentImproves antioxidant activityCosmetic preparationsToilet preparationsMethionine biosynthesisPeptide
The invention relates to a selenium-rich peptide with high antioxidant activity and application thereof. The selenium-rich peptide has the following amino acid sequence: FLML or LAMMVL, sulfur element in methionine M in the FLML is substituted by selenium, and the selenium-rich peptide is marked as FLSeML; the sulfur element in the first methionine M in the LAMMVL is substituted by selenium. The selenium-rich peptide with high antioxidant activity is separated and purified from the selenium-rich moringa seed protein powder, and the selenium-rich peptide has high selenium content, high antioxidant activity and cell damage protection effect, and can block the interaction of Keap1-Nrf2.
Owner:SOUTH CHINA AGRI UNIV
Application of HLA-A*24:02 allele to detecting person drug eruptionrisk caused by metronidazole
ActiveCN109628575AReduce generationBlocking interactionMicrobiological testing/measurementHLA - Human leukocyte antigen geneMedicine
The invention discloses application of HLA-A*24:02 allele to detecting person drug eruption risk caused by metronidazole. The invention provides application of a substance for detecting whether persons have the HLA-A*24:02 allele or not to preparing a product for detecting or evaluating adverse drug reaction risk generated when persons respond to the metronidazole. Experiments show that the humanleukocyte antigen gene-HLA-A*24:02 allele is related to drug eruptionattacking caused by the metronidazole. The HLA-A*24:02 allele can serve as a marker gene for forecasting the drug eruption risk caused by the metronidazole.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV +1
Novel application of compound in prevention and/or treatment of diseases caused by coronavirus infection
The invention finds that the norzerelaldehyde and the cediranib can effectively block the combination of RBD and ACE2 protein, so that the norzerelaldehyde and the cediranib can be applied to prevention and / or treatment of diseases caused by coronavirus infection.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Anti-PD-L1/VEGF fusion protein
PendingCN113754776AExcellent blocking abilityBlocking interactionPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseHeavy chain
The invention relates to the technical field of fusion proteins, and particularly relates to an anti-PD-L1 / VEGF fusion protein. The fusion protein comprises an anti-PD-L1 antibody, a peptide linker L and a D2 structural domain of VEGFR 1. The N terminal of the D2 structural domain of VEGFR1 is connected to the C terminal of an anti-PD-L1 antibody heavy chain through the peptide linker L. The fusion protein has the potential of treating diseases related to PD-L1 and VEGF activity.
Owner:ZEDA BIOPHARMACEUTICALS INC
Applications of polypeptide in preparation of drugs for treatment or prevention of diabetic cardiomyopathy
ActiveCN104740606ABlocking interactionGood effectPeptide/protein ingredientsMetabolism disorderHigh fat dietDiabetic cardiomyopathy
The present invention discloses applications of a polypeptide capable of specifically binding with TRB3 or polypeptide derivatives in preparation of drugs for treatment or prevention of diabetic cardiomyopathy, wherein the amino acid sequence of the polypeptide is one selected from sequences represented by SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and the polypeptide derivative is a chimeric peptide formed by connecting the polypeptide and a cell-penetrating peptide. According to the present invention, the polypeptide or polypeptide derivatives can specifically bind with TRB3 so as to block the interaction between the TRB3 and the P62 protein, and the peptide derivatives such as Pep2-A1, Pep2-A2 and Pep2-A3 can be used for treating the high-fat diet-induced type 2 diabetes.
Owner:胡卓伟
Anti-SIRP alpha rabbit recombinant monoclonal antibody as well as preparation method and application thereof
ActiveCN114560940ABlocking interactionBiological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsComplementarity determining regionAntiendomysial antibodies
The invention relates to an anti-SIRP alpha rabbit recombinant monoclonal antibody as well as a preparation method and application thereof, amino acid sequences of heavy chain complementary determining regions HCDR1, HCDR2 and HCDR3 of the anti-SIRP alpha rabbit recombinant monoclonal antibody are amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 respectively, and amino acid sequences of light chain complementary determining regions LCDR1, LCDR2 and LCDR3 are amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 respectively. The anti-SIRP alpha rabbit recombinant monoclonal antibody has good specificity, can be used in ELISA (Enzyme-Linked Immunosorbent Assay) and a common flow detection method, most importantly, the antibody can block the interaction between CD47 protein and SIRP alpha protein, and has potential tumor immunotherapy value.
Owner:缔码生物科技(武汉)有限公司
A kind of preparation method of anti-tobacco potato virus y vaccine
The invention discloses a preparation method of an anti-tobacco potato Y virus vaccine. The method includes the following steps that 1, pCaPVX440-eIF4E-6 plasmids are prepared; 2, the pCaPVX440-eIF4E-6 is transferred to agrobacterium to prepare the anti-tobacco potato Y virus vaccine. The anti-tobacco potato Y virus vaccine prepared by means of the preparation method is suitable for prevention and control of tobacco PVY viruses and has an important practical value for prevention and control of diseases caused by the PVY viruses in the tobacco leaf production process. Compared with the prior art, the virus vaccine is good in specificity, good in safety, simple, convenient and quick to operate and low in cost.
Owner:中国烟草总公司黑龙江省公司烟草科学研究所 +1
A kind of odor-eliminating fragrance-retaining agent and its preparation method and application
ActiveCN112500937BPrevent volatilizationEasy to useInorganic/elemental detergent compounding agentsCationic surface-active compoundsBiotechnologyDeodorant
Owner:河南省生物基材料产业研究院有限公司 +1
Application of a polypeptide in the preparation of drugs for treating diabetic cardiomyopathy
ActiveCN104740606BBlocking interactionGood effectPeptide/protein ingredientsMetabolism disorderHigh fat dietDiabetic cardiomyopathy
The present invention discloses applications of a polypeptide capable of specifically binding with TRB3 or polypeptide derivatives in preparation of drugs for treatment or prevention of diabetic cardiomyopathy, wherein the amino acid sequence of the polypeptide is one selected from sequences represented by SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and the polypeptide derivative is a chimeric peptide formed by connecting the polypeptide and a cell-penetrating peptide. According to the present invention, the polypeptide or polypeptide derivatives can specifically bind with TRB3 so as to block the interaction between the TRB3 and the P62 protein, and the peptide derivatives such as Pep2-A1, Pep2-A2 and Pep2-A3 can be used for treating the high-fat diet-induced type 2 diabetes.
Owner:胡卓伟
Use of epirubicin hydrochloride in the preparation of an inhibitor capable of blocking the interaction between p97 and npl4
ActiveCN106309461BBlocking interactionImprove infection abilityOrganic active ingredientsAntiviralsAnti virusTherapeutic effect
The invention relates to the technical field of biology, and more specifically relates to a purpose of epirubicin hydrochloride in preparation of an inhibitor for blocking interaction p97 and Npl4. The function of epirubicin hydrochloride which can effectively block the interaction of p97 and Npl4 is firstly found, a RIG-I mediated IFNbeta signal pathway is promoted so as to increase the anti-virus infection capability, so that the treatment effect for virus infection is enhanced, and the epirubicin hydrochloride has clinical and market value.
Owner:CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI
Human leukocyte antigen gene detection kit for screening skin adverse reactions caused by sulfasalazine
ActiveCN104818316BBlocking interactionMicrobiological testing/measurementBiological testingMetaboliteAdverse drug reaction
The invention provides a human leukocyte antigen gene detection kit for screening skin drug adverse reaction caused by salazosulfapyridine, belongs to the technical field of biomedicine, and relates to a detection kit of human leukocyte antigen gene HLA-B*13:01, wherein the HLA-B*13:01 gene can be adopted as the marker gene of salazosulfapyridine-induced DRESS. According to the present invention, DNA is extracted from the peripheral blood of a patient, and the HLA-B*13:01 gene is detected by using the current method, such as PCR-SSO (sequence-specific oligonucleotide probe) method; and the HLA-B*13:01 gene detection kit of the present invention can be used for screening before the salazosulfapyridine use and screening the target drug for treatment of salazosulfapyridine-induced DRESS, wherein the screening before the salazosulfapyridine use can guide the clinical medication so as to reduce the occurrence of the salazosulfapyridine-induced DRESS, and the drug screening mainly act on the HLA-B*13:01 molecules in a targeting manner so as to block the interaction between the HLA-B*13:01 molecules and the salazosulfapyridine or the metabolites thereof in the pathogenesis.
Owner:FUDAN UNIV +1
Human leukocyte antigen gene detection kit for screening skin adverse reactions caused by clindamycin
ActiveCN106755291BBlocking interactionMicrobiological testing/measurementBiological material analysisAntigenMetabolite
The invention belongs to the technical field of biological medicine, and relates to a human leukocyte antigen HLA-B*51: 01 gene detection kit. An HLA-B*51: 01 gene can be used as a marker gene for predicting clindamycin-induced drug rash. The invention provides the application of the detection kit to typing of the HLA-B*51: 01 gene in a sample. The application comprises the following steps: extracting DNA from obtained peripheral blood of a patient, and detecting the HLA-B*51: 01 gene by a current method, such as a sequence-specific oligonucleotide probe (PCR-SSO) method. The HLA-B*51: 01 gene detection kit provided by the invention can be applied to screening and sifting of targeted drugs for treating the clindamycin-induced drug rash before the use of clindamycin; screening application can guide clinical drug use so as to reduce incidence of the clindamycin-induced drug rash; selecting application mainly acts on an HLA-B*51: 01 molecule in a targeted manner so as to block interaction between the HLA-B*51: 01 molecule and clindamycin or other metabolites during the drug rash.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV +1
Composite capsules comprising raloxifene, and vitamin D or its derivatives
A composite capsule and a method of preparing the same are provided. The composite capsule includes: a raloxifene separate layer including raloxifene or a pharmaceutically acceptable salt thereof; and a vitamin D separate layer including vitamin D or a derivative thereof, wherein the raloxifene separate layer and the vitamin D separate layer are separated from one another in the composite capsule.
Owner:HANMI PHARMA
Application of a polypeptide or its derivatives in the treatment of hypertensive cardiac hypertrophy
ActiveCN106063928BBlocking interactionRestoring autophagic flowPeptide/protein ingredientsVertebrate antigen ingredientsNucleotidePharmaceutical drug
The invention discloses application of a polypeptide able to specifically bind TRB3 or polypeptide derivative or polypeptide chimeric peptide in preparation of drugs or vaccines for prevention and / or treatment of hypertensive myocardial hypertrophy. The polypeptide has an amino acid sequence shown as SEQ ID NO:1, the amino acid sequence of the polypeptide derivative is a SEQ ID NO:1 derived amino acid sequence that is obtained by subjecting the amino acid sequence shown as SEQ ID NO:1 to substitution, deletion or adding by one or several amino acid residues and has the same activity to an amino acid residue sequence of SEQ ID NO:1, and the polypeptide chimeric peptide is formed by connecting the polypeptide or polypeptide derivative with a cell-penetrating peptide. The invention also further discloses a nucleotide fragment encoding the polypeptide or polypeptide derivative, and application of pharmaceutical compositions containing the polypeptide or polypeptide derivative or polypeptide chimeric peptide and the nucleotide sequence thereof in preparation of drugs or vaccines for prevention and / or treatment of hypertensive myocardial hypertrophy.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Application of hla-a*24:02 allele in detection of risk of metronidazole-induced drug eruption in humans
ActiveCN109628575BReduce generationBlocking interactionMicrobiological testing/measurementWhite blood cellPharmaceutical drug
The invention discloses the application of the HLA‑A*24:02 allele in detecting the risk of drug eruption caused by metronidazole in humans. The present invention provides the application of a substance for detecting whether a human has an HLA-A*24:02 allele in the preparation of a product for detecting or evaluating the risk of adverse drug reactions in response to metronidazole in humans. Experiments of the present invention prove that the human leukocyte antigen gene—HLA-A*24:02 allele is related to the onset of drug eruption caused by metronidazole. The HLA‑A*24:02 allele can be used as a marker gene to predict the risk of metronidazole-induced drug eruption.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV +1
Application of a polypeptide in the preparation of medicines for treating or preventing metabolic syndrome
ActiveCN104740605BBlocking interactionRestoring autophagic flowPeptide/protein ingredientsMetabolism disorderMedicineAmino acid
Owner:胡卓伟
Mineralized material for preventing and treating dentin hypersensitivity and resisting caries as well as preparation method and application of mineralized material
ActiveCN114533565ANon-pathogenicLarge specific surface areaImpression capsNanotechnologyCalcium biphosphateDentin hypersensitivity
The invention provides a mineralization material for preventing and treating dentin hypersensitivity and resisting caries as well as a preparation method and application thereof, and belongs to the technical field of dental materials. The mineralization material for preventing and treating dentin hypersensitivity and resisting caries is a calcium phosphate nano biomimetic mineralization material loaded with egg yolk immunoglobulin, can effectively seal exposed dentin tubules, can effectively inhibit growth of cariogenic bacteria streptococcus mutans, and has good safety.
Owner:TONGJI UNIV
Application of spd_0310 protein as a target in the preparation of drugs for preventing and treating Streptococcus pneumoniae infection
ActiveCN110812484BReduce conservatismHighly conservativeAntibacterial agentsOrganic active ingredientsAntimicrobial drugStreptococcus infection
The invention discloses the application of SPD_0310 protein as a target in the preparation of medicines for preventing and treating Streptococcus pneumoniae infection. In the present invention, it was found that the expression level of SPD_0310 in the triple mutant strain in which the three main iron transport genes of Streptococcus pneumoniae were knocked out at the same time was increased and could grow normally, indicating that the SPD_0310 protein may be involved in the interaction of various iron transport proteins. The present invention also found that the spd_0310 gene knockout strain has reduced infectivity to mice. Based on this, SPD_0310 can be used to prepare antibodies to the protein, so as to facilitate the development of antibody drugs. In addition, the present invention also found that the active center of the protein can bind heme, and proved that porphyrins can be used as substrates to compete with heme, indicating that porphyrins can be used as inhibitors of SPD_0310 to inhibit Streptococcus pneumoniae toxicity, which has broad application prospects in the field of antibacterial drugs.
Owner:JINAN UNIVERSITY
Application of a polypeptide specifically binding to trb3 in the treatment of abdominal aortic aneurysm
ActiveCN105079780BBlocking interactionRestoring autophagic flowPeptide/protein ingredientsAntineoplastic agentsTGE VACCINEBlood vessel
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com